At 8:45 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

PepGen Inc. (NASDAQ:PEPG) is one of the hot stocks to buy with huge upside potential. On October 9, BofA raised the firm’s price target on PepGen to $3 from $1 and maintained an Underperform rating on the shares. This sentiment came out as the firm updated its financial model to assign a standalone value to the DM1 program following positive early Phase 1 data that showed splicing correction. The DM1 program refers to the company’s investigational drug, PGN-EDODM1, for treating Myotonic Dystrophy Type 1/D ...

Group 1 - PepGen Inc. (NASDAQ: PEPG) has reported strong mean splicing correction data from its DM1 treatment in phase 1 trials, which is currently progressing to phase 2 [2] - The Value Lab focuses on long-only value investment ideas, aiming for a portfolio yield of approximately 4% and has seen success over the past five years by engaging in international markets [1] - The Valkyrie Trading Society consists of analysts sharing high conviction investment ideas that are downside limited and expected to yield non-correlated and outsized returns in the current economic environment [3]

Core Insights - Biotech stocks experienced strong after-hours gains, driven by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing [1] Group 1: Ovid Therapeutics Inc. (OVID) - Ovid Therapeutics saw a 7.69% increase in after-hours trading, reaching $1.40 after a regular session decline of 7.14% to $1.30 [2] - The stock's regular session selloff was marked by elevated trading volume of over 2.93 million shares, significantly above the average of 2.07 million shares [2] - Recent coverage from Lucid Capital initiated a Buy rating with a price target of $5.50, highlighting Ovid's pipeline assets in Phase 1 trials for drug-resistant epilepsies [3] Group 2: NeuroOne Medical Technologies Corp. (NMTC) - NeuroOne Medical Technologies rose 6.98% in after-hours trading to $0.9506 after a modest decline of 1.27% during the regular session [4] - The trading volume was relatively light at 134,720 shares, below the average of 315,000 shares [4] - The company announced a virtual roadshow webinar scheduled for October 7 to discuss operations and recent FDA clearance [5] Group 3: PepGen Inc. (PEPG) - PepGen experienced a 3.03% rise in after-hours trading, reaching $4.76 after closing at $4.62 [6] - The stock has surged over 120% in the past week due to positive clinical and financial updates [6] - A recent $100 million public offering was completed, expected to support the development of PGN-EDODM1 and PGN-EDO51 [9] Group 4: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals rose 5.81% in after-hours trading to $0.3900 after a 19.56% surge during the regular session [10] - The trading volume was significantly elevated at over 26 million shares, well above the average of 3.9 million shares [10] - The company recently announced a $9 million public offering priced at $0.30 per share [11] Group 5: Anika Therapeutics Inc. (ANIK) - Anika Therapeutics saw a 5.53% increase in after-hours trading, reaching $9.92 after closing at $9.40 [11] - The stock's regular session strength followed a quiet news cycle, with no new filings or press releases [12] - Anika is in focus ahead of its scheduled earnings report on October 30, 2025 [12]

Core Viewpoint - PepGen Inc. is identified as a promising investment opportunity with a significant price target increase and strong performance in clinical studies [1][2]. Group 1: Company Performance - H.C. Wainwright has reaffirmed a 'Buy' rating on PepGen Inc. and raised the price target from $8.00 to $12.00, indicating a potential increase of nearly 135% [1]. - The company achieved a 53.7% mean splicing correction in its FREEDOM single-dose study for DM1 patients, marking the highest level reported in this patient group to date [1][2]. - PepGen Inc. delivered a return of 34.04%, significantly outperforming the market average of 13.10%, reflecting an impressive outperformance of nearly 21% [3]. Group 2: Company Overview - PepGen Inc., based in Boston, Massachusetts, is a clinical-stage biotechnology company focused on oligonucleotide therapeutics for severe neuromuscular and neurologic diseases [3]. - The company was founded in 2018 and offers several therapeutic candidates, including PGN-EDO51, PGN-EDODM1, and PGN-EDO53 [3].

Group 1 - PepGen Inc. has successfully closed its underwritten public offering of 35,937,500 shares of common stock [1] - The offering included the full exercise of the underwriters' option to purchase an additional 4,687,500 shares [1] - The company is focused on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases [1]

Core Viewpoint - PepGen Inc. (NASDAQ:PEPG) experienced a significant stock price increase of 121.05% following positive results from its clinical trial for an experimental drug aimed at treating myotonic dystrophy type 1 (DM1) [1][3]. Group 1: Clinical Trial Results - The clinical trial demonstrated a 53.7% correction in the key genetic error associated with DM1 in patients administered 15 mg/kg of the drug candidate PGN-EDODM1, surpassing previous reports of splicing correction in DM1 patients [2]. - The study achieved all key objectives, including unprecedented splicing correction after a single dose of PGN-EDODM1 at 15 mg/kg, as stated by the EVP for research and development [3]. Group 2: Financial Actions - Following the positive trial results, PepGen initiated a $100 million public offering, which includes the sale of 31.25 million shares priced at $3.20 each [4]. - The proceeds from the public offering will be allocated to ongoing research and clinical development efforts, particularly for DM1 clinical trials, with remaining funds directed towards general corporate purposes [5].

Core Viewpoint - PepGen Inc. has seen a significant increase in stock price following the release of positive clinical data from its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1, indicating strong investor interest and confidence in the company's pipeline [1][8]. Clinical Data Summary - The FREEDOM-DM1 study reported a mean splicing correction of 53.7% in patients receiving a 15 mg/kg dose of PGN-EDODM1, with all six patients (100%) showing improved splicing correction [3][4]. - Previous doses of 5 mg/kg and 10 mg/kg showed mean splicing corrections of 12.3% and 29.1%, respectively, indicating a greater than dose-proportional increase in splicing correction with higher doses [4]. - Muscle tissue concentrations of PGN-EDODM1 also increased proportionally across the different doses at Day 28 [4]. Safety and Tolerability - PGN-EDODM1 was generally well-tolerated at the 15 mg/kg dose, with no serious treatment-related adverse events reported [4]. - All treatment-related adverse events were mild or moderate and transient, with one case of dose-limiting toxicity classified as a mild adverse event that resolved without intervention [5][6]. Future Expectations - PepGen plans to report results from the FREEDOM2-DM1 MAD study 5 mg/kg cohort in Q1 2026 and will begin dosing the 10 mg/kg cohort in the same timeframe [7]. - The company has priced an offering of 31.25 million shares at $3.20 per share, expecting gross proceeds of $100 million [7]. Stock Performance - As of the latest publication, PepGen shares rose by 122.18% to $5.91, trading within a 52-week range of $0.88 to $9.93 [8].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - PepGen Inc. (PEPG) is up 151% at $6.68 [3] - 22nd Century Group, Inc. (XXII) is up 27% at $1.93 [3] - Immuneering Corporation (IMRX) is up 23% at $11.36 [3] - uniQure N.V. (QURE) is up 10% at $52.58 [3] - Lithium Americas Corp. (LAC) is up 9% at $6.60 [3] - Jasper Therapeutics, Inc. (JSPR) is up 9% at $2.55 [3] - American Shared Hospital Services (AMS) is up 8% at $2.75 [3] - PSQ Holdings, Inc. (PSQH) is up 7% at $3.06 [3] - K Wave Media Ltd. (KWM) is up 7% at $2.48 [3] - ClearPoint Neuro, Inc. (CLPT) is up 5% at $20.48 [3] Premarket Losers - Transocean Ltd. (RIG) is down 14% at $3.11 [4] - Cyclerion Therapeutics, Inc. (CYCN) is down 12% at $2.83 [4] - CarMax, Inc. (KMX) is down 11% at $50.38 [4] - ARB IOT Group Limited (ARBB) is down 11% at $10.45 [4] - SHF Holdings, Inc. (SHFS) is down 10% at $6.49 [4] - Digital Brands Group, Inc. (DBGI) is down 10% at $6.21 [4] - Aqua Metals, Inc. (AQMS) is down 9% at $5.29 [4] - Akanda Corp. (AKAN) is down 8% at $3.96 [4] - Galecto, Inc. (GLTO) is down 8% at $3.88 [4] - Platinum Analytics Cayman Limited (PLTS) is down 7% at $11.12 [4]

Core Points - PepGen Inc. announced an underwritten public offering of common stock and pre-funded warrants, leading to a 112.4% increase in its share price to $5.65 in pre-market trading [1] - Other notable stock movements include OFA Group rising 49.6% to $1.99 due to a partnership announcement, and WORK Medical Technology Group increasing 50.4% to $0.1693 after a significant drop the previous day [5] - Lithium Americas Corp. gained 36.8% to $8.21 following reports of Trump officials seeking an equity stake in the company related to a $2.26 billion loan renegotiation [5] Gainers - Immuneering Corporation rose 30% to $12.00 after pricing a $175 million public offering and a $25 million private placement [5] - 22nd Century Group, Inc. gained 37.7% to $2.08 after securing $9.5 million from an insurance claim settlement [5] - ClearPoint Neuro, Inc. increased by 12.8% to $21.76 after a previous gain of 58% [5] Losers - SeaStar Medical Holding Corporation dipped 43.3% to $0.7035 following a recommendation to continue a pivotal trial [5] - Cemtrex, Inc. shares fell 27.7% to $0.4530 after approving a 1-for-15 reverse stock split [5] - Lunai Bioworks Inc. declined 25.3% to $0.1290 after announcing a 10-for-1 reverse stock split [5]